In October, when GSK agreed to a $2.2 billion settlement to resolve approximately 80,000 lawsuits | With a $2.2 billion ...

who did not know that GSK had for decades concealed an internal study that implicated the Company’s liability to Zantac users; and (4) as a result, Defendants’ positive statements about the ...

Defendants represented to investors that GSK removed Zantac from the market “[b]ased on information available at the time and correspondence with regulators,” and that GSK was “continuing ...

who did not know that GSK had for decades concealed an internal study that implicated the Company's liability to Zantac users. The truth began to emerge on August 10, 2022, when a Deutsche Bank ...

GSK claims to investors that its decision to remove Zantac from the market was "based on information available at the time and correspondence with regulators," and that the Company was "continuing ...

who did not know that GSK had for decades concealed an internal study that implicated the Company’s liability to Zantac users. When the true details entered the market, the lawsuit claims that ...

GSK was forced to pay around £1.8bn to settle thousands of cases in US courts in October amid claims Zantac caused cancer. Pharmaceutical giant GSK has hiked its 2031 sales forecast to more than ...

Operating profits dropped by 40% to £4 billion due to a £1.8 billion settlement following lawsuits linked to its former heartburn drug Zantac. GSK said it expects core operating profits to rise ...

GSK was forced to pay around £1.8bn to settle thousands of cases in US courts in October amid claims Zantac caused cancer. Pharmaceutical giant GSK has hiked its 2031 sales forecast to more than £40bn ...